AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells

被引:73
作者
Agarwal, C
Chandraratna, RAS
Johnson, AT
Rorke, EA
Eckert, RL
机构
[1] CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106
[2] CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106
[3] CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106
[4] CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106
[5] CASE WESTERN RESERVE UNIV,SCH MED,DEPT ENVIRONM HLTH SCI,CLEVELAND,OH 44106
[6] ALLERGAN PHARMACEUT INC,DEPT CHEM,RETINOID RES,IRVINE,CA 92713
[7] ALLERGAN PHARMACEUT INC,DEPT BIOL,IRVINE,CA 92713
关键词
D O I
10.1074/jbc.271.21.12209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Retinoids are important physiological agents that regulate epithelial cell differentiation and proliferation. The importance of these agents in regulating growth, development, and differentiation has led to a search for new retinoid agonists and antagonists. In the present manuscript we show that AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells. Treatment of ECE16-1 cells with natural or synthetic retinoids reduces cytokeratin K5, K6, K14, K16, and K17 levels, increases cytokeratin K7, K8, and K19 levels, increases retinoic acid receptor-beta (RAR beta) mRNA levels, suppresses proliferation, and alters cell morphology. Co-treatment with AGN193109 prevents these responses. Half-maximal and maximal antagonism is observed at a molar ratio of AGN193109: retinoid agonist of 1:1 and 10:1, respectively. When administered alone AGN193109 has no agonist activity. Thus, AGN193109, which binds to RAR alpha, RAR beta, and RAR gamma with K-d values = 2, 2, and 3 nM, respectively, but is unable to bind to the retinoid X receptors, is a highly active antagonist of retinoid action in ECE16-1 cells.
引用
收藏
页码:12209 / 12212
页数:4
相关论文
共 43 条
[1]  
AGARWAL C, 1994, CANCER RES, V54, P2108
[2]  
Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521
[3]  
AGARWAL C, 1991, CANCER RES, V51, P3982
[4]   RETINOID-DEPENDENT TRANSCRIPTIONAL SUPPRESSION OF CYTOKERATIN GENE-EXPRESSION IN HUMAN EPIDERMAL SQUAMOUS-CELL CARCINOMA-CELLS [J].
AGARWAL, C ;
RORKE, EA ;
BOYCE, M ;
HOWARD, J ;
CRISH, J ;
HUFEISEN, S ;
ECKERT, RL .
DIFFERENTIATION, 1993, 52 (02) :185-191
[5]   A RETINOIC ACID RECEPTOR-ALPHA ANTAGONIST SELECTIVELY COUNTERACTS RETINOIC ACID EFFECTS [J].
APFEL, C ;
BAUER, F ;
CRETTAZ, M ;
FORNI, L ;
KAMBER, M ;
KAUFMANN, F ;
LEMOTTE, P ;
PIRSON, W ;
KLAUS, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (15) :7129-7133
[6]   SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF STILBENE RETINOID ANALOGS SUBSTITUTED WITH HETEROAROMATIC CARBOXYLIC-ACIDS [J].
BEARD, RL ;
CHANDRARATNA, RAS ;
COLON, DF ;
GILLETT, SJ ;
HENRY, E ;
MARLER, DK ;
SONG, T ;
DENYS, L ;
AREFIEG, T ;
KLEIN, E ;
GIL, DW ;
WHEELER, L ;
KOCHHAR, DM ;
DAVIES, PJA .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (15) :2820-2829
[7]   A NEW RETINOIC ACID RECEPTOR IDENTIFIED FROM A HEPATOCELLULAR-CARCINOMA [J].
BENBROOK, D ;
LERNHARDT, E ;
PFAHL, M .
NATURE, 1988, 333 (6174) :669-672
[9]   IDENTIFICATION OF A 2ND HUMAN RETINOIC ACID RECEPTOR [J].
BRAND, N ;
PETKOVICH, M ;
KRUST, A ;
CHAMBON, P ;
DETHE, H ;
MARCHIO, A ;
TIOLLAIS, P ;
DEJEAN, A .
NATURE, 1988, 332 (6167) :850-853
[10]   SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF CONFORMATIONALLY RESTRICTED, ACETYLENIC RETINOID ANALOGS [J].
CHANDRARATNA, RAS ;
GILLETT, SJ ;
SONG, TK ;
ATTARD, J ;
VULIGONDA, S ;
GARST, ME ;
AREFIEG, T ;
GIL, DW ;
WHEELER, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (05) :523-527